Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.

Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE.

Med Oncol. 2011 Dec;28 Suppl 1:S152-61. doi: 10.1007/s12032-010-9658-1. Epub 2010 Aug 21.

PMID:
20730572
2.

Adjuvant chemotherapy in older women with early-stage breast cancer.

Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP; CALGB Investigators.

N Engl J Med. 2009 May 14;360(20):2055-65. doi: 10.1056/NEJMoa0810266. Erratum in: N Engl J Med. 2009 Oct 22;361(17):1714. Magrinat, Gutav [corrected to Magrinat, Gustav].

3.

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.

Kim ES, Mauer AM, William WN Jr, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS.

Cancer. 2009 Apr 15;115(8):1713-22. doi: 10.1002/cncr.24148.

4.

Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.

Stinchcombe TE, Mauer AM, Hodgson LD, Herndon JE 2nd, Lynch TJ, Green MR, Vokes EE; Cancer and Leukemia Group B.

J Thorac Oncol. 2008 Nov;3(11):1301-7. doi: 10.1097/JTO.0b013e318187494a.

5.

Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.

Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE.

J Thorac Oncol. 2008 Sep;3(9):1003-11. doi: 10.1097/JTO.0b013e31818396a4.

6.

A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.

Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, Qian J, Hagey AE, Gordon GB.

J Thorac Oncol. 2008 Jun;3(6):631-6. doi: 10.1097/JTO.0b013e318174e01f.

7.

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ.

J Clin Oncol. 2008 Feb 20;26(6):848-55. doi: 10.1200/JCO.2007.13.8081.

PMID:
18281656
8.

Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L, Mauer AM.

J Thorac Oncol. 2008 Jan;3(1):59-67. doi: 10.1097/JTO.0b013e31815e8566.

9.

The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib.

Buckingham LE, Coon JS, Morrison LE, Jacobson KK, Jewell SS, Kaiser KA, Mauer AM, Muzzafar T, Polowy C, Basu S, Gale M, Villaflor VM, Bonomi P.

J Thorac Oncol. 2007 May;2(5):414-22.

10.

Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.

Choong NW, Mauer AM, Hoffman PC, Rudin CM, Winegarden JD 3rd, Villano JL, Kozloff M, Wade JL 3rd, Sciortino DF, Szeto L, Vokes EE.

J Thorac Oncol. 2006 Mar;1(3):245-51.

11.

The role of cooperative groups in cancer clinical trials.

Mauer AM, Rich ES, Schilsky RL.

Cancer Treat Res. 2007;132:111-29. Review. No abstract available.

PMID:
17305018
12.

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.

Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22.

13.

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE.

Clin Cancer Res. 2005 Dec 1;11(23):8418-24.

14.

Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.

Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K, Szeto L, Vokes EE.

Ann Oncol. 2005 Aug;16(8):1320-5. Epub 2005 May 26.

PMID:
15919687
15.

A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer.

Gupta S, Mauer AM, Ryan CW, Taber DA, Samuels BL, Fleming GF; University of Chicago Phase II Network.

Am J Clin Oncol. 2005 Feb;28(1):65-9.

PMID:
15685037
16.

Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.

Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR.

Int J Oncol. 2004 Dec;25(6):1677-83.

PMID:
15547705
17.

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ.

Invest New Drugs. 2004 Nov;22(4):449-58.

PMID:
15292715
18.

A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.

Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, Hoffman PC, Vokes EE; University of Chicago Phase II Network; Ohio State University.

Ann Oncol. 2004 Jun;15(6):915-20.

PMID:
15151948
19.

A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer.

Vokes EE, Gordon GS, Mauer AM, Rudin CM, Krauss SA, Szeto L, Golomb HM, Hoffman PC.

Clin Lung Cancer. 2000 Nov;2(2):128-32.

PMID:
14731323
20.

Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer.

Vokes EE, Charoentum C, Gordon GS, Rudin CM, Krauss SA, Hoffman PC, Mauer AM, Lee S, Watson S.

Clin Lung Cancer. 2002 May;3(4):265-70.

PMID:
14662035
21.

Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer.

Mauer AM, Ansari RH, Hoffman PC, Krauss SA, Taber D, Tembe SA, Gabrys GT, Cotter T, Schumm LP, Szeto L, Vokes EE.

Ann Oncol. 2003 May;14(5):722-8.

PMID:
12702526
22.

A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain.

Villano JL, Mauer AM, Vokes EE.

Ann Oncol. 2003 Apr;14(4):656-8. No abstract available.

PMID:
12649117
23.

A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.

Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, Vokes EE.

Lung Cancer. 2003 Feb;39(2):191-6.

PMID:
12581572
24.

Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.

Hoffman PC, Cohen EE, Masters GA, Haraf DJ, Mauer AM, Rudin CM, Krauss SA, Huo D, Vokes EE.

Lung Cancer. 2002 Oct;38(1):65-71.

PMID:
12367795
25.

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, George CM, Szeto L, Vokes EE.

Ann Oncol. 2002 Apr;13(4):539-45.

PMID:
12056703
26.

Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.

Eng C, Mauer AM, Fleming GF, Bertucci D, Rotmensch J, Jacobs RH, Ratain MJ.

Ann Oncol. 2001 Dec;12(12):1743-7.

PMID:
11843253
27.

A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.

Vokes EE, Gordon GS, Rudin CM, Mauer AM, Watson S, Krauss S, Arrieta R, Golomb HM, Hoffman PC.

Invest New Drugs. 2001;19(4):329-33.

PMID:
11561694
28.

A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest.

George CM, Haraf DJ, Mauer AM, Krauss SA, Hoffman PC, Rudin CM, Szeto L, Vokes EE.

Invest New Drugs. 2001;19(4):303-10.

PMID:
11561689
29.

American Society of Pediatric Hematology/Oncology Distinguished Career Award goes to Beatrice C. Lampkin, M.D.

Mauer AM.

J Pediatr Hematol Oncol. 2001 Mar-Apr;23(3):146. No abstract available.

PMID:
11305714
30.

Lung cancer.

Hoffman PC, Mauer AM, Vokes EE.

Lancet. 2000 Feb 5;355(9202):479-85. Review. Erratum in: Lancet 2000 Apr 8;355(9211): 1280.

PMID:
10841143
31.

Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy.

Flamholz R, Tran T, Grad GI, Mauer AM, Olopade OI, Ellman MH, McKinsey JF, Jeon HR, Baron JM, Baron BW.

J Clin Apher. 1999;14(4):171-6. Review.

PMID:
10611626
32.

First two cases of immune hemolytic anemia associated with ceftizoxime.

Shammo JM, Calhoun B, Mauer AM, Hoffman PC, Baron JM, Baron BW.

Transfusion. 1999 Aug;39(8):838-44.

PMID:
10504119
34.
35.

Multimodality therapy for esophageal cancer: an emerging role.

Vokes EE, Mauer AM.

Cancer J Sci Am. 1998 Jul-Aug;4(4):226-9. No abstract available.

PMID:
9689980
36.

A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.

Masters GA, Mauer AM, Hoffman PC, Wyka D, Samuels BL, Krauss SA, Watson S, Golomb H, Vokes EE.

Ann Oncol. 1998 Jun;9(6):677-80.

PMID:
9681085
37.

Ifosfamide-based three-drug combination regimens in non-small cell lung cancer.

Vokes EE, Masters GA, Mauer AM, Hoffman PC, Watson S, Golomb HM.

Semin Oncol. 1998 Feb;25(1 Suppl 2):19-22.

PMID:
9535207
38.

Phase I study of docetaxel with concomitant thoracic radiation therapy.

Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE.

J Clin Oncol. 1998 Jan;16(1):159-64.

PMID:
9440738
39.

Clinical studies of docetaxel (Taxotere) and concomitant chest therapy.

Vokes EE, Masters GA, Mauer AM, Haraf DJ, Hoffman PC, Golomb HM.

Semin Oncol. 1997 Aug;24(4 Suppl 14):S14-26-S14-29.

PMID:
9335521
40.

Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer.

Vokes EE, Mauer AM, Hoffman PC, Masters G, Watson S, Golomb HM.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-67-S12-69.

PMID:
9331125
41.

Psychosocial protocol for childhood cancer. A conceptual model.

Lauria MM, Hockenberry-Eaton M, Pawletko TM, Mauer AM.

Cancer. 1996 Sep 15;78(6):1345-56. No abstract available.

PMID:
8826961
42.

Dosing of oral etoposide normalized for body surface area.

Miller AA, Mauer AM, Tolley EA.

Cancer Invest. 1995;13(5):487-91.

PMID:
7552815
43.
44.

Cocaine-induced platelet defects.

Jennings LK, White MM, Sauer CM, Mauer AM, Robertson JT.

Stroke. 1993 Sep;24(9):1352-9.

45.

Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.

Miller AA, Tolley EA, Niell HB, Griffin JP, Mauer AM.

J Clin Oncol. 1993 Jun;11(6):1179-88.

PMID:
8388920
46.
47.

Biologic markers for cancer: the search for the Holy Grail continues.

Mauer AM.

J Lab Clin Med. 1992 Dec;120(6):828-30. No abstract available.

PMID:
1453104
48.

Assessment of lumiaggregometry for research and clinical laboratories.

White MM, Foust JT, Mauer AM, Robertson JT, Jennings LK.

Thromb Haemost. 1992 May 4;67(5):572-7.

PMID:
1519217
49.

Should there be intervention to alter serum lipids in children?

Mauer AM.

Annu Rev Nutr. 1991;11:375-91. Review. No abstract available.

PMID:
1892706
50.

Acute lymphocytic leukemia in children: recent progress and future prospects.

Mauer AM.

Acta Paediatr Jpn. 1990 Oct;32(5):479-84. Review. No abstract available.

PMID:
2284924

Supplemental Content

Loading ...
Support Center